-DOCSTART- -X- O
The -X- _ O
treatment -X- _ O
of -X- _ O
multiple -X- _ B-Patient
sclerosis -X- _ I-Patient
( -X- _ I-Patient
MS -X- _ I-Patient
) -X- _ I-Patient
has -X- _ O
changed -X- _ O
over -X- _ O
the -X- _ O
last -X- _ O
20 -X- _ O
years. -X- _ O
All -X- _ O
immunotherapeutic -X- _ O
drugs -X- _ O
target -X- _ O
relapsing -X- _ B-Patient
remitting -X- _ I-Patient
MS -X- _ I-Patient
( -X- _ I-Patient
RRMS -X- _ I-Patient
) -X- _ I-Patient
and -X- _ O
it -X- _ O
still -X- _ O
remains -X- _ O
a -X- _ O
medical -X- _ O
challenge -X- _ O
in -X- _ O
MS -X- _ O
to -X- _ O
develop -X- _ O
a -X- _ O
treatment -X- _ O
for -X- _ O
progressive -X- _ O
forms. -X- _ O
The -X- _ O
most -X- _ O
common -X- _ O
injectable -X- _ B-Intervention
disease-modifying -X- _ I-Intervention
therapies -X- _ I-Intervention
in -X- _ O
RRMS -X- _ B-Patient
include -X- _ O
Î²-interferons -X- _ B-Intervention
1a -X- _ I-Intervention
or -X- _ I-Intervention
1b -X- _ I-Intervention
and -X- _ I-Intervention
glatiramer -X- _ I-Intervention
acetate. -X- _ I-Intervention
However -X- _ O
, -X- _ O
one -X- _ O
of -X- _ O
the -X- _ O
major -X- _ O
challenges -X- _ O
of -X- _ O
injectable -X- _ B-Intervention
disease-modifying -X- _ I-Intervention
therapies -X- _ I-Intervention
has -X- _ O
been -X- _ O
poor -X- _ O
treatment -X- _ B-Outcome
adherence -X- _ I-Outcome
with -X- _ I-Outcome
approximately -X- _ I-Outcome
50 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
patients -X- _ I-Outcome
discontinuing -X- _ I-Outcome
the -X- _ I-Outcome
therapy -X- _ I-Outcome
within -X- _ I-Outcome
the -X- _ I-Outcome
first -X- _ I-Outcome
year. -X- _ I-Outcome
Herein -X- _ O
, -X- _ O
we -X- _ O
go -X- _ O
back -X- _ O
to -X- _ O
the -X- _ O
basics -X- _ O
to -X- _ O
understand -X- _ O
the -X- _ O
immunopathophysiology -X- _ O
of -X- _ O
MS -X- _ O
to -X- _ O
gain -X- _ O
insights -X- _ O
in -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
new -X- _ O
improved -X- _ O
drug -X- _ O
treatments. -X- _ O
We -X- _ O
present -X- _ O
current -X- _ O
disease-modifying -X- _ O
therapies -X- _ O
( -X- _ O
interferons -X- _ O
, -X- _ O
glatiramer -X- _ O
acetate -X- _ O
, -X- _ O
dimethyl -X- _ O
fumarate -X- _ O
, -X- _ O
teriflunomide -X- _ O
, -X- _ O
fingolimod -X- _ O
, -X- _ O
mitoxantrone -X- _ O
) -X- _ O
, -X- _ O
humanized -X- _ B-Intervention
monoclonal -X- _ I-Intervention
antibodies -X- _ I-Intervention
( -X- _ I-Intervention
natalizumab -X- _ I-Intervention
, -X- _ I-Intervention
ofatumumab -X- _ I-Intervention
, -X- _ I-Intervention
ocrelizumab -X- _ I-Intervention
, -X- _ I-Intervention
alemtuzumab -X- _ I-Intervention
, -X- _ I-Intervention
daclizumab -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ O
emerging -X- _ B-Intervention
immune -X- _ I-Intervention
modulating -X- _ I-Intervention
approaches -X- _ I-Intervention
( -X- _ I-Intervention
stem -X- _ I-Intervention
cells -X- _ I-Intervention
, -X- _ I-Intervention
DNA -X- _ I-Intervention
vaccines -X- _ I-Intervention
, -X- _ I-Intervention
nanoparticles -X- _ I-Intervention
, -X- _ I-Intervention
altered -X- _ I-Intervention
peptide -X- _ I-Intervention
ligands -X- _ I-Intervention
) -X- _ I-Intervention
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
MS -X- _ O
. -X- _ O

